Adam Mecca is a Psychiatry physician affiliated with Yale University. OpenAlex indexes 201 publications with 7,018 citations (h-index 32); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
20 York St
T-209, Yale New Haven Hospital
New Haven, CT 065103220
Telephone
203-688-2259Registry record last updated 19 Jan 2016.
Clinical trials
- A Multiple Ascending Dose Study in Healthy Volunteers and Patients With Alzheimer's Disease
Sponsor: Allyx Therapeutics
- Evaluating the Safety, Tolerability, Pharmacokinetics and Receptor Occupancy of BMS-984923
Sponsor: Yale University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year20259 payments
- Axsome Therapeutics, Inc.Program year20251 payment
- ABBVIE INC.Program year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
2 NIH research awards on record, funded 2018–2023 per NIH RePORTER. The latest:
- A Phase 1b Multiple Ascending Dose Study of the Safety and Tolerability of BMS-984923 in Alzheimer's Disease
Yale University
FY2023$988,498R01AG073177 - A Phase 1b Multiple Ascending Dose Study of the Safety and Tolerability of BMS-984923 in Alzheimer's Disease
Yale University
FY2022$1,543,652R01AG073177 - Investigation of molecular changes in mGluR5 and SV2A to study synaptic alterations in Alzheimer's disease using PET.
Yale University
FY2022$195,393K23AG057794
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- The Impact of Cognitive Impairment on Cardiovascular Disease
Journal of the American College of Cardiology
2025 - Synaptic loss and its association with symptom severity in Parkinson’s disease
npj Parkinson s Disease
2024 - A pilot study to evaluate the effect of CT1812 treatment on synaptic density and other biomarkers in Alzheimer’s disease
Alzheimer s Research & Therapy
2024
Similar KOLs
Other experts from the same institution or the same specialty.
John Krystal, MD
Yale University
Lajos Pusztai, MD
Yale University
Lee Schwamm, MD
Yale University
Naftali Kaminski, MD
Yale University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”